BELLUS Health announces closing of Innodia acquisition

    Company announces change to senior management team

    LAVAL, QC, July 17 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ:   BLUS;
TSX: BLU, formerly known as Neurochem Inc.) announced today the closing of the
acquisition of Innodia Inc. that it had previously announced on July 16, 2008.
    As a result of this acquisition, BELLUS Health is also announcing a
change at the management level in the field of research. Nigel Levens, Ph.D.,
Chief Scientific Officer of Innodia Inc. will take on the position of Vice
President, Research at BELLUS Health while Daniel Delorme, Ph.D., BELLUS
Health's current Vice President, Research, will be leaving the Company to
pursue other interests.
    "I am very pleased to welcome Dr. Levens to the Company," said
Dr. Francesco Bellini, Chairman, President and CEO of BELLUS Health. "The
expertise he demonstrated in drug discovery for metabolic diseases at Innodia,
will serve us very well at BELLUS Health. I also want to thank Dr. Delorme for
his valuable contribution to the Company during his tenure with us and wish
him great success in his future endeavours."
    Dr. Levens brings to the position 27 years of teaching and research in
the field of metabolic and cardiovascular diseases in both Europe and North
America. Prior to joining Innodia in 2006, he worked as Head of Biology for
Biovitrum AB of Sweden, which specializes in metabolic diseases such as
Type II diabetes, obesity, and metabolic syndrome. From 1998-2003, he served
as Head of the Division of Metabolic Diseases for the Servier Research Group
in France and prior to that as Head of Obesity Pharmacology for Novartis
Pharma in Basel, Switzerland. Educated in both the United Kingdom and the
United States, Dr. Levens holds a B.Sc. (Hons.) in Physiology and
Biochemistry, and a Ph.D. in Physiology from the University of Southampton in
the United Kingdom and conducted a postdoctoral fellowship in pharmacology at
the University of Virginia.

    About BELLUS Health

    BELLUS Health is a global health company focused on the development and
commercialization of products to provide innovative health solutions to
address critical unmet medical needs.

    To Contact BELLUS Health

    For additional information on BELLUS Health and its programs, please call
the Canada and United States toll-free number 1-877-680-4500 or visit the Web
Site at

    Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond BELLUS Health
Inc.'s (formerly known as Neurochem Inc.) control. Such risks include but are
not limited to: the impact of general economic conditions, general conditions
in the pharmaceutical and/or nutraceutical industry, changes in the regulatory
environment in the jurisdictions in which the BELLUS Health Group does
business, stock market volatility, fluctuations in costs, and changes to the
competitive environment due to consolidation, that actual results may vary
once the final and quality-controlled verification of data and analyses has
been completed, as well as other risks disclosed in public filings of BELLUS
Health Inc. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance, if any, on any forward-looking statements
included in this news release. These statements speak only as of the date made
and BELLUS Health Inc. is under no obligation and disavows any intention to
update or revise such statements as a result of any event, circumstances or
otherwise, unless required by applicable legislation or regulation. Please see
the Annual Information Form of BELLUS Health Inc. for further risk factors
that might affect the BELLUS Health Group and its business.

For further information:

For further information: Lise Hébert, Ph.D., Vice President, Corporate
Communications, (450) 680-4570,

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890